Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival
Conditions
Lung Cancer - NSCLC
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
Positron-Emission Tomography, PET Scan, Non-Small-Cell Lung Carcinoma, Radiation Oncology, SUV
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Intervention
Name: Positron Emission Tomography
Type: Procedure
Overall Status
Recruiting
Summary
The poor prognosis in the early-stage of lung cancer is due to potential worsening of the disease (local relapse, metastasis), to insufficient efficacy and toxicity of actual treatments.

FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose consumption. Then, this exam is used for pathology staging, target volume definition for RT, and treatment efficiency few months after RT or CRT. Our assumption is that an FDG-PET exam during the course of the RT or CRT might be predictive of the treatment efficiency few months later.

In this study, the investigators propose to perform 4 FDG-PET: first "PET1" before radiotherapy, second "PET2" during the radiotherapy (see RTEP1), third and fourth "PET3" "PET4" 3month and 12 month after the therapy.

The investigators will investigate the performances of FDG-PET performed during the RT or CRT for the prediction of the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, the investigators would be able to optimize the planning treatment during the course of the therapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histologically confirmed non-small cell lung cancer

- Fertile patients must use effective contraception

- WHO performance status <2

- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (≥ 10 mm with spiral CT scan)

Exclusion Criteria:

- Pregnant or lactating females

- Baseline fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scan without any target lesion

- Unable to under PET CT evaluation

- other concurrent investigational agents

- No Planning to undergo curative intent radiotherapy

- familial, social, geographic, or psychological conditions that would preclude study participation

- Prior malignancy progressive disease
Location
Centre Henri Becquerel
Rouen, France
Status: Recruiting
Contact: Arthur DUMOUCHEL, CRA - 00.33.02.32.08.29.61 - arthur.dumouchel@rouen.fnclcc.fr
Start Date
November 2007
Completion Date
June 2014
Sponsors
Centre Henri Becquerel
Source
Centre Henri Becquerel
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page